Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma.

摘要: Extra-domain B of fibronectin (EDB-FN) is an alternatively spliced form with high expression in the extracellular matrix neovascularized tissues and malignant cancer cells. In this study, we evaluated practicality using EDB-FN as a biomarker therapeutic target for gliomas (MGs), representative intractable diseases involving brain tumors. Methods: The microarray- sequence-based patient transcriptomic database 'Oncopression' tissue microarray MG samples were analyzed. data extracted from 23,344 17 types to assess its effectiveness selectivity molecular target. To strengthen results analysis, utility marker was verified active EDB-FN-targeting ultrasmall lipidic micellar nanoparticles (~12 nm), which had drug-loading capacity efficiently internalized by cells vitro vivo. Results: Brain tumors 1.42-fold cancer-to-normal ratio (p < 0.0001), second highest among cancers after head neck cancer. Patient analysis showed that high-expression group 5.5-fold higher risk progression than low-expression 0.03). By labeling docetaxel-containing micelles bipodal aptide targeting (termed APTEDB-DSPE-DTX), generated could specifically bind cells, leading superior antitumor efficacy compared nontargeting controls. Conclusions: Taken together, these show can be effective drug delivery MG.